Fluoroquinolone-Based Organic Salts (GUMBOS) with Antibacterial Potential.
GUMBOS
antibacterial
ciprofloxacin
combination drug therapy
fluoroquinolones
moxifloxacin
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
28 Oct 2023
28 Oct 2023
Historique:
received:
29
09
2023
revised:
25
10
2023
accepted:
25
10
2023
medline:
15
11
2023
pubmed:
14
11
2023
entrez:
14
11
2023
Statut:
epublish
Résumé
Antimicrobial resistance is a silent pandemic considered a public health concern worldwide. Strategic therapies are needed to replace antibacterials that are now ineffective. One approach entails the use of well-known antibacterials along with adjuvants that possess non-antibiotic properties but can extend the lifespan and enhance the effectiveness of the treatment, while also improving the suppression of resistance. In this regard, a group of uniform materials based on organic salts (GUMBOS) presents an alternative to this problem allowing the combination of antibacterials with adjuvants. Fluoroquinolones are a family of antibacterials used to treat respiratory and urinary tract infections with broad-spectrum activity. Ciprofloxacin and moxifloxacin-based GUMBOS were synthesized via anion exchange reactions with lithium and sodium salts. Structural characterization, thermal stability and octanol/water partition ratios were evaluated. The antibacterial profiles of most GUMBOS were comparable to their cationic counterparts when tested against Gram-positive
Identifiants
pubmed: 37958698
pii: ijms242115714
doi: 10.3390/ijms242115714
pmc: PMC10650486
pii:
doi:
Substances chimiques
Fluoroquinolones
0
Salts
0
Anti-Bacterial Agents
0
Anions
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fundação para a Ciência e Tecnologia
ID : 2020.05142.BD
Organisme : National Science Foundation
ID : CHE-1905105
Organisme : Fundação para a Ciência e Tecnologia
ID : 2021.00921.CEECIND/CP1662/CT0005
Organisme : Fundação para a Ciência e Tecnologia
ID : UIDB/50006/2020
Organisme : Fundação para a Ciência e Tecnologia
ID : UIDP/50006/2020
Références
Int J Mol Sci. 2020 Jun 30;21(13):
pubmed: 32630159
J Med Pharm Chem. 1962 Sep;5:1063-5
pubmed: 14056431
Pathogens. 2021 Feb 01;10(2):
pubmed: 33535562
Future Microbiol. 2015;10(7):1111-23
pubmed: 26119479
Clin Infect Dis. 2019 Jun 18;69(1):1-11
pubmed: 30715222
ACS Infect Dis. 2021 Sep 10;7(9):2637-2649
pubmed: 34467755
J Enzyme Inhib Med Chem. 2006 Apr;21(2):211-4
pubmed: 16789435
ChemMedChem. 2015 Sep;10(9):1480-3
pubmed: 26190053
Microb Biotechnol. 2009 Jan;2(1):40-61
pubmed: 21261881
Acta Pharm. 2020 Dec 31;71(3):365-382
pubmed: 36654099
Molecules. 2020 Jul 17;25(14):
pubmed: 32709149
ACS Omega. 2020 May 28;5(22):12637-12648
pubmed: 32548447
Biomolecules. 2020 Feb 06;10(2):
pubmed: 32041305
ACS Omega. 2021 Jan 25;6(4):2626-2637
pubmed: 33553880
Br J Clin Pharmacol. 2018 Jul;84(7):1401-1409
pubmed: 29451320
PLoS Pathog. 2018 Mar 1;14(3):e1006805
pubmed: 29494701
Trends Microbiol. 2014 Aug;22(8):438-45
pubmed: 24842194
Int J Mol Sci. 2022 Jun 02;23(11):
pubmed: 35682940
Int J Oncol. 1993 Sep;3(3):473-6
pubmed: 21573387
Eur J Pharm Sci. 2012 Aug 30;47(1):21-7
pubmed: 22579663
Bioorg Med Chem Lett. 2016 Aug 1;26(15):3770-3
pubmed: 27287371
Expert Rev Mol Med. 2011 Feb 23;13:e5
pubmed: 21342612
Nat Rev Microbiol. 2019 Mar;17(3):141-155
pubmed: 30683887
Molecules. 2015 Apr 10;20(4):6466-87
pubmed: 25867831
Transfus Med Hemother. 2012 Oct;39(5):328-34
pubmed: 23801924
Pharmaceutics. 2020 Mar 02;12(3):
pubmed: 32131540
Nat Rev Microbiol. 2015 Jan;13(1):42-51
pubmed: 25435309
Int J Pharm. 2014 Jul 20;469(1):179-89
pubmed: 24746413
Int J Nanomedicine. 2011;6:3049-56
pubmed: 22162661
Sci Rep. 2020 Aug 6;10(1):13206
pubmed: 32764602
J Med Microbiol. 2017 May;66(5):551-559
pubmed: 28504927
Clin Microbiol Rev. 2016 Oct;29(4):819-36
pubmed: 27464994
Molecules. 2021 Mar 07;26(5):
pubmed: 33799954
ACS Comb Sci. 2020 Sep 14;22(9):440-445
pubmed: 32691584
Molecules. 2021 Oct 29;26(21):
pubmed: 34770974
Anal Chim Acta. 2020 Aug 22;1126:38-51
pubmed: 32736723
Int J Mol Sci. 2023 Jan 11;24(2):
pubmed: 36674923
Antibiotics (Basel). 2022 Dec 19;11(12):
pubmed: 36551498
Molecules. 2016 Mar 28;21(4):268
pubmed: 27043501
J Pharm Sci. 2023 Jan;112(1):195-203
pubmed: 35948159
ACS Appl Mater Interfaces. 2019 Aug 7;11(31):27548-27557
pubmed: 31310100
Chemosphere. 2022 Dec;308(Pt 2):136237
pubmed: 36049636
J Antimicrob Chemother. 2020 Dec 1;75(12):3576-3581
pubmed: 32830243
ChemMedChem. 2019 May 6;14(9):907-911
pubmed: 30735308
ScientificWorldJournal. 2014;2014:254215
pubmed: 25431781
Microbiol Spectr. 2016 Apr;4(2):
pubmed: 27227291
J Antimicrob Chemother. 2013 Jun;68(6):1312-8
pubmed: 23447139
Antimicrob Resist Infect Control. 2017 May 15;6:47
pubmed: 28515903
Anal Chem. 2014 Aug 5;86(15):7184-91
pubmed: 25017178
Antimicrob Agents Chemother. 2008 Jun;52(6):1924-8
pubmed: 18378704
Pharmacotherapy. 1988;8(1):3-33
pubmed: 2836821
Int J Mol Sci. 2023 Feb 02;24(3):
pubmed: 36769243
Pharmaceutics. 2020 Jul 23;12(8):
pubmed: 32717808
Microb Drug Resist. 2020 Jun;26(6):537-544
pubmed: 31825276
Ann Hematol. 2010 Sep;89(9):935-7
pubmed: 20127091
Profiles Drug Subst Excip Relat Methodol. 2014;39:299-431
pubmed: 24794910
J Org Chem. 1997 Oct 17;62(21):7512-7515
pubmed: 11671879
Antimicrob Agents Chemother. 1985 May;27(5):688-91
pubmed: 3160301
Biochim Biophys Acta. 2012 Nov;1818(11):2563-71
pubmed: 22664062
ACS Omega. 2020 Feb 21;5(8):4125-4132
pubmed: 32149241
Clin Infect Dis. 2001 Mar 15;32 Suppl 1:S16-22
pubmed: 11249824
Perspect Medicin Chem. 2014 Aug 28;6:25-64
pubmed: 25232278
ACS Infect Dis. 2015;1(11):512-522
pubmed: 26925460
PLoS One. 2018 Jan 4;13(1):e0190729
pubmed: 29300775
Eur J Med Chem. 2020 Jan 1;185:111810
pubmed: 31678743
Antiviral Res. 2001 Oct;52(1):25-32
pubmed: 11530185
Expert Opin Drug Saf. 2012 Mar;11(2):221-33
pubmed: 22074343